Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
Rhea-AI Summary
Eli Lilly (NYSE: LLY) has completed its acquisition of Centessa Pharmaceuticals, a clinical-stage company focused on orexin receptor 2 agonists for narcolepsy and other sleep-wake disorders. Lilly plans to advance Centessa's clinical portfolio to address unmet needs in conditions driven by disrupted sleep and wakefulness.
Positive
- Acquisition adds clinical-stage orexin receptor 2 agonist portfolio to Lilly
- Expands Lilly's pipeline in narcolepsy and other sleep-wake disorders
- Completed transaction enables Lilly to control and prioritize development efforts
Negative
- None.
News Market Reaction – LLY
In the Jun 24 session, LLY gained 0.92%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Previous Acquisition Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 26 | Infectious disease deals | -0.0% | Multiple vaccine-focused acquisitions to expand infectious disease prevention portfolio. | |
| Apr 27 | Hematology acquisition | -1.8% | Ajax buyout adding a Phase 1 Type II JAK2 inhibitor for myelofibrosis. | |
| Apr 20 | Gene therapy acquisition | -0.8% | Kelonia deal to broaden in vivo CAR-T and genetic medicine capabilities. | |
| Mar 31 | Centessa agreement | +3.7% | Initial Centessa acquisition announcement expanding sleep medicine and OX2R agonist pipeline. | |
| Feb 09 | Cell therapy acquisition | -1.3% | Orna acquisition to add in vivo CAR-T platform for autoimmune diseases. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
orexin receptor 2 agonists medical
orexin system medical
narcolepsy medical
sleep-wake disorders medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
"The orexin system plays a fundamental role in human brain health, governing wakefulness, alertness, and the stability of sleep in ways that, when disrupted, can be profoundly disabling," said Carole Ho, Lilly executive vice president and president, Lilly Neuroscience. "For people living with narcolepsy, that disruption is severe and life-altering. Orexin's reach extends further to diseases impacted by disrupted sleep, and so does the unmet need. Centessa has built a clinical portfolio with the depth to explore both, and Lilly intends to pursue that potential with urgency."
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of Lilly, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the benefits of Lilly's acquisition of Centessa Pharmaceuticals, Lilly's neuroscience platform and development plans, Centessa's clinical-stage pipeline of programs targeting sleep disorders, including its lead program targeting orexin dysfunction, and reflects Lilly's current beliefs and expectations. However, as with any such undertaking, there are substantial risks and uncertainties in implementing the acquisition and in the process of drug research, development, and commercialization. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that the acquisition will achieve the results discussed in this press release or that the acquisition will yield commercially successful products. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this press release.
Refer to: | Jessica Bardoulas; jessica.bardoulas@lilly.com (Media) |
Michael Czapar; czapar_michael_c@lilly.com (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-completes-acquisition-of-centessa-pharmaceuticals-to-advance-treatments-for-sleep-wake-disorders-302808668.html
SOURCE Eli Lilly and Company